- Home
- ZION vs AXSM Comparison
ZION vs AXSM Comparison
Compare ZION & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | AXSM |
|---|---|---|
| Founded | 1873 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 9.0B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ZION | AXSM |
|---|---|---|
| Price | $59.05 | $185.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 21 |
| Target Price | $62.40 | ★ $190.57 |
| AVG Volume (30 Days) | ★ 1.5M | 868.9K |
| Earning Date | 01-20-2026 | 02-17-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | ★ 21.41 | N/A |
| EPS | ★ 6.01 | N/A |
| Revenue | ★ $3,314,000,000.00 | $561,263,000.00 |
| Revenue This Year | $8.00 | $67.10 |
| Revenue Next Year | $4.39 | $58.73 |
| P/E Ratio | $10.15 | ★ N/A |
| Revenue Growth | 8.37 | ★ 65.83 |
| 52 Week Low | $39.32 | $86.99 |
| 52 Week High | $62.26 | $191.50 |
Technical Indicators
Market Signals| Indicator | ZION | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 68.61 |
| Support Level | $58.75 | $172.05 |
| Resistance Level | $62.26 | $191.50 |
| Average True Range (ATR) | 1.47 | 6.27 |
| MACD | -0.17 | 0.98 |
| Stochastic Oscillator | 24.41 | 81.98 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.